Skip to main content
HR 2700 108th Congress House Health Access to health care Ambulatory care Congress Congressional reporting requirements Cost accounting Drugs Governmental investigations Hemophilia Hospital rates Medicare Orphan drugs Overhead costs Pharmacies Social Welfare

Medicare Patient Access to Drugs for Rare Diseases Act of 2003

Introduced: July 10, 2003 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 23, 2003
Referred to the Subcommittee on Health.
Jul 22, 2003
Referred to the Subcommittee on Health.
Jul 10, 2003
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 10, 2003
Introduced in House
 Plain-English summary Congressional Research Service

Medicare Patient Access to Drugs for Rare Diseases Act of 2003 - Amends title XVIII (Medicare) of the Social Security Act to revise the methodology by which payment for orphan drugs and biologicals is made under the Medicare prospective payment system for hospital outpatient department (OPD) services.

Directs the Secretary to report to specified congressional committees on payment for orphan drugs and biologicals and blood clotting factors for individuals with hemophilia in the OPD setting, including recommendations for either continuing or discontinuing the exclusion of such drugs and biologicals from payment under Medicare.

Provides for a moratorium on decreases in payment rates for orphan drugs and biologicals and blood clotting factors for certain individuals with hemophilia.

What's happening now July 23, 2003

Referred to the Subcommittee on Health.

 Committees of jurisdiction 4
 Cosponsors 5
All 5 Democratic 3 Republican 2